| Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (NCT07634289) | Olivia Newton-John Cancer Research Institute | 2026-12-01 |
| OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma (NCT07739017) | Olivia Newton-John Cancer Research Institute | 2026-12-01 |
| Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma (NCT07712770) | Olivia Newton-John Cancer Research Institute | 2026-10-01 |
| Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. (NCT05788081) | Olivia Newton-John Cancer Research Institute | 2023-08-31 |
| A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (NCT05182931) | Olivia Newton-John Cancer Research Institute | 2022-07-14 |
| Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (NCT04962126) | Olivia Newton-John Cancer Research Institute | 2021-08-17 |
| Combination Immunotherapy in Rare Cancers Under InvesTigation (NCT04969887) | Olivia Newton-John Cancer Research Institute | 2021-08-03 |
| Bioimaging Study of 89Zr-M7824 in NSCLC (NCT04297748) | Olivia Newton-John Cancer Research Institute | 2020-06-01 |
| Medical Imaging of Cachexia (NCT04127981) | Olivia Newton-John Cancer Research Institute | 2019-03-28 |
| A Trial of KB004 in Patients With Glioblastoma (NCT03374943) | Olivia Newton-John Cancer Research Institute | 2017-12-05 |
| A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers (NCT02923934) | Olivia Newton-John Cancer Research Institute | 2017-08-22 |
| Pembrolizumab + CVA21 in Advanced NSCLC (NCT02824965) | Olivia Newton-John Cancer Research Institute | 2017-08-09 |